CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
Conditions: Hematologic Malignancy; ALL, Childhood; AML, Childhood; Lymphoma; MDS

Interventions: Drug: Fludarabine; Drug: Cyclophosphamide; Drug: CD70-CAR T cell infusion (Autologous); Drug: Mesna

Sponsors: St. Jude Children’s Research Hospital

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 25, 2024Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments